[Patients with fractures are in the front line for osteoporosis treatment but how to treat?].
Välimäki
M J
MJ
D019386:Alendronate / Q000627:therapeutic use; D015519:Bone Density / Q000187:drug effects; D002116:Calcitonin / Q000627:therapeutic use; D012968:Etidronic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control*; D006297:Health Services Accessibility / Q000458:organization & administration / Q000592:standards; D006801:Humans; D010024:Osteoporosis / Q000150:complications / Q000175:diagnosis* / Q000517:prevention & control*; D010819:Physician's Role; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D000068296:Risedronic Acid; D012307:Risk Factors
D020849:Raloxifene Hydrochloride; D002116:Calcitonin; D000068296:Risedronic Acid; D012968:Etidronic Acid; D019386:Alendronate